By achieving production levels measured in multi-Metric Tons (MT) for the key biopolymer ingredient for BAYSE, and at efficiencies demonstrating commercial viability, ZymoChem is paving the way to ...

Aurion Biotech, Inc. (AURN) has filed to raise $100 million in an IPO of its common ... Management said it plans to use the IPO net proceeds as detailed here: to fund the clinical development ...

ZymoChem, the biotech company creating sustainable materials for everyday products, announces the successful commercial-scale production of the key biopolymer ingredient used in its groundbreaking ...

This information can be used to design optimal isotretinoin treatment ... for systemic acne treatment with oral antibiotics like doxycycline, minocycline, trimethoprim-sulfamethoxazole ...

Our round-up of financings in the biotech sector ... Medicines brought in $100 million in a first-round financing led by RA Capital Management and Forbion that will be used to develop a pipeline ...

Embryonic stem cells (ESCs) can be propagated indefinitely in culture, while retaining the ability to differentiate into any cell type in the organism. The molecular and cellular mechanisms ...

The Legend Biotech-partnered CAR-T hasn't yet reached ... which came to market around a year before Carvykti, saw sales top the $100 million level in the third quarter of 2022, taking its nine ...

These results indicate that nuclear entrapment of BCR–ABL can be used as a therapeutic strategy ... antibody against phosphotyrosine (Upstate Biotechnology, Waltham, Massachusetts), or 1 μg ...

A SCOTTISH biotech innovation centre added 100 new members to its network in less ... more sustainable materials and products through the use of bio-based alternatives. As well as support for ...

Samples were mounted using DAPI Fluoromount-G (Southern Biotech; Cat #0100-20). Fluorescence images were acquired using Confocal Leica TCS SP5 (Leica Microsystems), and Leica application software LAS ...

These biological processes can be used to efficiently break down waste and produce materials with lower pollution, water, land, and energy use than traditional methods. The number of applications ...

LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase II drugs for Pleomorphic Liposarcoma does not have ...